World-first clinical trial to test promising new approach to target triple-negative breast cancer

Metastatic triple-negative breast cancer has limited treatment options and is commonly diagnosed in younger women, aged under 40.  But a promising combination therapy could offer a new approach to target this highly aggressive and treatment-resistant type of breast cancer. QIMR Berghofer Professor Sudha Rao and Kazia Therapeutics CEO Dr John Friend share the incredible story that led to their collaboration, and a world-first clinical trial.